Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Inspyr Therapeutics Inc (OTCQB:NSPX)

0.25
Delayed Data
As of 2:17pm ET
 +0.05 / +25.00%
Today’s Change
0.17
Today|||52-Week Range
4.99
-54.55%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.7M

Company Description

Inspyr Therapeutics, Inc. is a pharmaceutical company, which focuses on the development of prodrug cancer therapeutics for the treatment of solid tumors. The company's prodrug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. Its technology platform combines a powerful cytotoxin with a patented prodrug delivery system that targets the release of the drug within the tumor. The company was founded by Craig A. Dionne, John T. Issacs and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

Contact Information

Inspyr Therapeutics, Inc.
31200 Via Colinas
Westlake Village California 91362
P:(818) 661-6302
Investor Relations:

Employees

Shareholders

Individual stakeholders2.70%
Mutual fund holders--
Other institutional--

Top Executives

Christopher P. LowePresident, CEO, CFO, CAO & Executive Director
Ronald L. ShazerChief Medical Officer & Senior Vice President
Michael ElliottVice President-Clinical Operations
Matthew BoxerVice President & Head-Translational Medicine
David MaloneyVice President & Head-Translational Medicine